ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a fixed-dose combination oral tablet containing chloroquine phosphate and primaquine phosphate, two antimalarial agents with complementary mechanisms of action. This combination targets both erythrocytic and exoerythrocytic stages of Plasmodium parasites, providing comprehensive antimalarial coverage. The product is used for the treatment and prevention of malaria in endemic regions.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a declining commercial team and potential workforce restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE offers limited career advancement given the product's mature lifecycle and LOE approaching status. Opportunities exist in emerging markets, generic competition management, and operational excellence, but this is not a flagship growth platform.
Brand ManagerSales Representative
Worked on ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.